Jaguar Health (JAGX) Q1 2026 earnings summary

Executive summary

• Net revenue surged 816% year-over-year and 527% sequentially in Q1 2026, driven by a transformative U.S. out-license agreement for Mytesi and Canalevia-CA1 with Future Pak, resulting in $16 million upfront and additional milestone payments.

• Achieved net income of $8.7 million for Q1 2026, a turnaround from a $10.6 million net loss in Q1 2025, primarily due to $19 million license revenue from the Future Pak agreement.

• Strategic focus shifted to developing crofelemer powder formulation for rare intestinal failure indications, targeting pediatric MVID and SBS-IF, with ongoing pivotal and phase II trials and NDA submission targeted for mid-2027.

• Clinical milestones include proof-of-concept data showing significant reductions in parenteral support for pediatric MVID and SBS-IF patients, with presentations at major gastroenterology conferences.

• Reduced sales and marketing expenses after licensing Mytesi and Canalevia to Future Pak, shifting focus to pipeline development.

Financial highlights

• Total net revenue reached $22 million in Q1 2026, up from $2.2 million in Q1 2025 and $3.2 million in Q4 2025, with license and grant revenue at $19.1 million.

• Income from operations improved by $19.6 million, shifting from a $9.4 million loss to $10.2 million income year-over-year.

• Non-GAAP recurring EBITDA loss narrowed to $6.4 million from $9.7 million year-over-year.

• Net loss attributable to common shareholders decreased by $3.5 million to $7.0 million.

• Cash and restricted cash totaled $10.1 million at March 31, 2026.

Outlook and guidance

• Focus on securing a development and commercialization partner for crofelemer's powder formulation for MVID and SBS-IF, with NDA submission for MVID targeted for mid-2027 and phase II SBS-IF results expected around the same time.

• Management expects continued losses and negative cash flows, with future operations dependent on additional financing and successful product commercialization.

• Anticipated breakthrough therapy designation from FDA and accelerated EMA pathways for crofelemer.

• Additional $2 million license payment expected upon completion of post-closing conditions.